NewGenIvf Group Ltd (NIVF) reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of 272,140 stock options to acquire Class B Ordinary Shares at an exercise price of US$0.0001 per share. The options vest upon grant and expire on August 17, 2033, granted under the company’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026. Following this award, the reporting person holds 345,787 stock options in total.
NewGenIvf Group Ltd (NIVF) granted its Chairman & CEO, Siu Wing Fung Alfred, stock options for 272,140 Class B Ordinary Shares. The options have an exercise price of US$0.0001 per share, vest immediately upon grant, and expire on August 17, 2033. Following this award, the reporting person holds 345,787 stock options directly. The grant was made under the company’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026.
NewGenIVF Group Limited entered into an Amendment and Exchange Agreement with an institutional investor under which, on August 14, 2026, the investor’s existing convertible notes and related warrants were exchanged for a new senior convertible note with an aggregate principal amount of $7,105,468.75. A related Leak-Out Agreement restricts sales of Class A ordinary shares issuable upon conversion of the new note. The restructuring removed a prior requirement that a significant percentage of proceeds from new capital raises be used to prepay the notes under a June 16, 2026 Repurchase and Forbearance Agreement, and is described by the company as intended to provide greater flexibility in managing future financing and capital structure.
NewGenIVF Group Limited reported that its total outstanding Class A shares now stand at 5,919,948, following share issuances connected to strategic share purchase agreements to acquire a 3% equity interest in K25.ai.
Using the July 30, 2026 closing price of $0.85 per share, the company’s Market Value of Listed Securities reached US$5,031,956.
NewGenIVF Group Limited reports net profit attributable to shareholders of US$9.9 million for the year ended December 31, 2025, and net assets of about US$25.98 million. The company also highlights an agreed 13% stake in K25.ai, subject to completion of share purchase agreements.
Based on a current implied K25.ai valuation of US$200 million, this stake is valued at about US$26 million and is expected to generate an unrealized gain of approximately US$8.5 million, which NewGen views as strengthening its balance sheet. After a planned issuance of 2,500,000 Class A ordinary shares, total outstanding Class A shares are expected to reach about 5,900,000.
NewGenIVF Group Limited agreed to acquire an additional 3% equity interest in K25.ai for aggregate consideration of US$7.5 million, implying a US$250 million equity valuation for K25.ai. The consideration comprises US$3.75 million in cash or digital assets and 2,500,000 newly issued Class A ordinary shares at US$1.50 per share.
Upon completion, NewGen’s ownership in K25.ai is expected to rise from 10% to 13%. Issuing approximately 2.5 million shares is expected to increase total outstanding shares to about 5.9 million and strengthen market capitalization above US$5 million, supporting ongoing Nasdaq listing compliance. The shares will be issued as restricted securities under Section 4(a)(2) and/or Regulation S, and closing is subject to customary conditions.
NewGenIvf Group Ltd director Siu Wing Fung Alfred received a grant of 73,647 Employee Share Options as part of his compensation. These options have an exercise price of $0.0001 per Class B ordinary share and expire on July 8, 2033.
The options were granted under the company’s 2024 Share Incentive Plan and an option agreement dated July 8, 2026. They vest over 36 months, with 10% vesting on August 8, 2026 and the remainder vesting in approximately 2.6% monthly tranches, aligning incentives over a multi-year period.
NewGenIvf Group Ltd director receives a new equity award. Director Fong Hei Yue Tina was granted employee share options covering 73,647 Class B ordinary shares at an exercise price of $0.0001 per share.
The options were granted under the 2024 Share Incentive Plan and vest over 36 months, with 10% vesting on August 8, 2026 and the remaining options vesting in roughly 2.6% monthly tranches. Following this grant, the filing shows 73,647 options held directly.
NewGen Group Limited is highlighting a new growth push around its advanced cytometry platform, backed by an independent Big Four valuation. A planned UAE-based cell sorting and cytometry leasing entity has been assigned a midpoint equity value of about US$19 million as of May 31, 2026, following an earlier Big Four valuation of the underlying cytometry IP at US$17.9 million in October 2025. The business will lease devices to clinics on fixed and variable-consumable terms while running a centralized sorting hub in the UAE, targeting rising infertility and medical tourism across the GCC. NewGen has also appointed industry veteran Nadeem Malik as Senior Strategic Advisor to lead commercialization and regional expansion.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued share classes at a ratio of one new share for every three existing shares. This is being carried out by the Board under the BVI Business Companies Act and the company’s M&A without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on July 6, 2026, and the Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that same day under the symbol NIVF with a new CUSIP G0544E501. The number of outstanding Class A ordinary shares will change from 10,259,764 to approximately 3,419,922.
Every three existing Class A ordinary shares will automatically combine into one new share, with no fractional shares issued; holders who would otherwise receive a fraction will instead receive one full post-split share at the participant level. All options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three, rounded to the nearest whole share, while par value remains nil and the company’s unlimited authorized share capital is unchanged.